Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -18.22 | -22.77 | -19.26 | |
| Graham Fair Price | -15.17 | 16.57 | 19.53 | |
| PEG | -71.14 | 0.26 | -0.90 | |
| Price/Book | -4.47 | 2.51 | 2.63 | |
| Price/Cash Flow | 27.63 | -21.11 | -29.16 | |
| Prices/Earnings | -15.94 | -6.05 | -5.22 | |
| Price/Sales | -93.76 | 89.84 | -1438.79 | |
| Price/FCF | 27.63 | -21.11 | -29.16 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -60.06 | 0.91 | 2.29 | |
| Operating Margin | -94.60 | -3.94 | 72.97 | |
| ROA | 16.04 | -0.09 | -0.10 | |
| ROE | -0.13 | -0.10 | 17.61 | |
| ROIC | -0.16 | -0.10 | 36.66 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.04 | -0.03 | -53.77 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.07 | 0.19 | 176.19 | |
| EPS QOQ | -0.06 | 0.23 | 301.71 | |
| FCF QOQ | 0.11 | -0.30 | 186.94 | |
| Revenue QOQ | -1.16 | 16.09 | 1287.58 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | < 0.005 | 100.00 | |
| Days Sales Outstanding (DSO) | -1711.55 | 113.30 | -93.38 | |
| Inventory Turnover | 0.00 | 2512000.00 | 100.00 | |
| Debt/Capitalization | 0.10 | 0.10 | -2.34 | |
| Quick Ratio | 8.23 | 8.45 | 2.66 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 11.61 | 10.85 | -6.54 | |
| Cash | 10.08 | 8.29 | -17.84 | |
| Capex | -0.02 | -0.03 | -56.17 | |
| Free Cash Flow | -1.05 | -1.29 | -23.36 | |
| Revenue | -0.02 | 0.30 | 1329.72 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad